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Objective: The Sorin Bicarbon prosthesis (Sorin Biomedica, Saluggia, Italy) is a
bileaflet valve with curved-profile leaflets, a rolling hinge mechanism, and a pyro-
lytic carbon–coated titanium alloy housing and sewing ring. Although the Sorin
Bicarbon prosthesis has been implanted in greater than 80,000 patients, and refer-
ence values on the hemodynamic performance of valve prostheses are needed to
avoid patient-prosthesis mismatch, few Doppler echocardiographic data are avail-
able on the prosthesis in the aortic position. The aim of this study is to provide a
detailed echocardiographic evaluation of the hemodynamic performance and regres-
sion of left ventricular hypertrophy after aortic valve replacement with the Sorin
Bicarbon prosthesis.
Methods: The study included 182 patients who received a 21-mm (n  61) or
23-mm (n  121) Sorin Bicarbon prosthesis for pure or prevalent aortic stenosis
who underwent serial echocardiograms at 3, 6, and 12 months after aortic valve
replacement.
Results: Mean and peak gradients significantly decreased (P  .001) during fol-
low-up to values of 12 3 and 22 6 mm Hg for the 21-mm prosthesis and values
of 11  4 and 19  6 mm Hg for the 23-mm prosthesis at 1 year. Left ventricular
mass index showed a 17% decrease to 120  27 g/m2 in recipients of the 21-mm
prosthesis (P  .001) and a 21% decrease to 123  29 g/m2 in recipients of the
23-mm prosthesis (P  .001). A larger prosthesis size was the only predictor of a
higher left ventricular mass index regression. Among recipients of the 21-mm
prosthesis, body surface area of greater than 1.85 m2 was associated with a lower
regression of left ventricular mass index. The effective orifice area index was 1.00
0.11 and 1.08  0.14 cm2/m2 in recipients of the 21-mm and 23-mm prostheses,
respectively.
Conclusions: Size 21 mm and 23 mm Sorin Bicarbon prostheses show low
transprosthetic gradients, with significant reduction of left ventricular mass index
during the first postoperative year. The reported effective orifice areas might be
useful for aortic valve replacement in patients with a small aortic annulus to avoid
patient-prosthesis mismatch.
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The Sorin Bicarbon prosthesis (SBP) is athird-generation bileaflet valve (Sorin Bio-medica, Saluggia, Italy) that has been clini-cally available in Europe since 1990 andimplanted in over 80,000 patients. The hous-ing of this prosthesis is made of a titanium
alloy and is therefore slim, providing a significantly larger
orifice while maintaining structural stability and integrity to
obtain a better hemodynamic. Moreover, the 2 leaflets with
curved profiles open to 80° from a 20° horizontal axis,
providing low transprosthetic pressure gradient, low turbu-
lence, and partition of the flow into 3 hydraulically equiv-
alent bloodstreams.1,2 An innovative hinge mechanism al-
lows the leaflets to move by rolling rather than by sliding,
thus exposing all areas to a full washing effect at each point
of the cardiac cycle. Finally, the housing, sewing ring, and
leaflets are coated with a thin layer of pyrolytic carbon
(Carbofilm; Sorin), a nonthrombogenic material. Although
hydrodynamic in vitro studies have demonstrated that the
SBP has a lower forward-flow pressure decrease compared
with that of other flat-leaflet models,3,4 few data are avail-
able on the hemodynamic performance of the SBP in the
aortic position in vivo.5-7 Moreover, reference values on the
hemodynamic performance of valve prostheses are needed
to avoid patient-prosthesis mismatch,8 particularly for
small-sized (23 mm) prostheses, which represent more
than two thirds of mechanical aortic prostheses inserted
annually.9 The aim of the present study was to provide a
detailed Doppler echocardiographic evaluation of 21-mm
and 23-mm SBPs in the aortic position and to evaluate the
regression of left ventricular hypertrophy during the first
year after aortic valve replacement (AVR). This was per-
formed by means of serial echocardiograms at 3, 6, and 12
months after AVR, with assessment of transprosthetic pres-
sure gradients, effective orifice area index (EOAi), and left
ventricular mass index (LVMi).
Methods
Patient Population
Between March 1995 and May 2000, among the 885 patients
undergoing AVR, the 224 receiving a 21-mm or 23-mm standard
SBP for pure or prevalent aortic stenosis were considered eligible
for inclusion in the study. Patients with preoperative left ventric-
ular ejection fractions of less than 30%, patients with more than
mild aortic regurgitation, and patients undergoing simultaneous
aortic and mitral valve replacement were excluded, whereas pa-
tients undergoing coronary bypass grafting, mitral valve repair, or
ascending aorta replacement associated with AVR were included.
The 199 patients meeting the inclusion criteria were followed up
by means of clinical and echocardiographic evaluation at our
outpatient clinic at 3, 6, and 12 months. One patient with paraval-
vular leak and 16 who did not have a complete clinical and
echocardiographic evaluation at our outpatient clinic at all fol-
low-up intervals were subsequently excluded from data analysis.
The remaining 182 patients (61 with a 21-mm SBP and 121 with
a 23-mm SBP) form the basis of the present report. The main
characteristics of this group of patients are summarized in Table 1.
Surgical Technique
The majority of patients had pure or prevalent aortic stenosis
caused by calcific valvular degeneration. All operations were per-
formed by using moderately hypothermic cardiopulmonary bypass
with topical cooling and infusion of blood cardioplegic solution
into the aortic root or coronary ostia. Prostheses were implanted in
the supra-annular position by means of multiple interrupted
stitches buttressed with subannular Teflon felt, with the prosthesis
oriented perpendicular to the interventricular septum. Administra-
tion of warfarin was started on the second postoperative day with
a target international normalized ratio of 2.5 and maintained there-
after.
Echocardiographic Study
At each postoperative interval, a transthoracic 2-dimensional (2-D)
color Doppler echocardiogram was performed. Standard M-mode
and 2-D measurements were collected according to the American
Society of Echocardiography criteria10; the left ventricular outflow
diameter (DLVOT) was averaged from 3 parasternal long-axis
zoomed frames frozen in early systole from the trailing edge of the
left septal echocardiogram to the leading edge of the anterior
mitral leaflet echocardiogram. All Doppler measurements were
averaged over 3 cycles in patients with sinus rhythm or over 5
cycles in those with atrial fibrillation.
TABLE 1. Patient characteristics
Sex (male/female) 96/86 (53%/47%)
Age (y) 64 10
Age 70 y 49 (27%)
BSA (m2) 1.76 0.16
Atrial fibrillation 24 (13%)
Pacemaker 7 (4%)
NYHA class (mean) 2.4 0.6
Valvular lesion
Pure stenosis 119 (65%)
Mixed defect 63 (35%)
Cause:
Calcific degeneration 132 (73%)
Prosthesis dysfunction 4 (2%)
Rheumatic 44 (24%)
Congenital 2 (1%)
Left ventricular ejection fraction (%) 48 10
LVMi (g/m2) 152 33
Peak aortic gradient (mm Hg) 79 31
Mean aortic gradient (mm Hg) 52 22
Aortic valve area index (cm2/m2) 0.50 0.16
Urgent operation 3 (2%)
Procedure associated with AVR 41 (23%)
Coronary artery bypass grafting 33 (18%)
Mitral valve repair 5 (3%)
Ascending aorta replacement 3 (2%)
Valve size
21 mm 61 (34%)
23 mm 121 (66%)
Surgery for Acquired Cardiovascular Disease De Carlo et al
338 The Journal of Thoracic and Cardiovascular Surgery ● August 2003
A
CD
Subaortic peak (PV1) and mean velocities, mean pressure gra-
dient (MG1), and velocity-time integral (VTI1) were measured
from the pulsed-wave Doppler recordings in the 5-chamber apical
view, with the sample volume placed just below the point of fast
flow acceleration. Transprosthetic peak (PV2) and mean velocities,
mean pressure gradient (MG2), and velocity-time integral (VTI2)
were measured from the continuous-wave Doppler recordings
from the apical view or from the right intercostal and suprasternal
views. From these data, we calculated the peak gradient across the
prosthesis (from the long form of the modified Bernoulli equation:
PG  4[PV22  PV12]), the mean gradient (MG MG2 MG1),
the effective orifice area (EOA; EOA  [DLVOT/2]2[VTI1/
VTI2]), the EOAi (EOAi  EOA/BSA), and the LVMi (from
Devereux’s formula).11
Statistical Analysis
Data are presented as means  SD and as simple percentages.
Both 1-factor and 2-factor repeated-measures analyses of variance
(ANOVA) with the Bonferroni multiple comparison test were used
to assess the influence of time and prosthesis size on transpros-
thetic mean and peak gradients, EOAi, and LVMi. The  value for
the Bonferroni test was set at .05. Statistical analysis was per-
formed with the NCSS 2000 software (Statistical Solutions Ltd,
Cork, Ireland).
Results
Clinical Status
At the 1-year follow-up, the mean New York Heart Asso-
ciation (NYHA) class was 1.0  0.8, with 145 (80%)
patients in functional class I, 31 (17%) in class II, 4 (2%) in
class III, and 2 (1%) in class IV. Mean NYHA class did not
significantly differ between the recipients of the 21-mm and
23-mm SBPs (1.1  0.6 vs 0.9  0.9, P  .10).
Hemodynamic Data
Mean left ventricular ejection fraction in the entire popula-
tion was 48%  10%, 51%  9%, 52%  10%, and 51%
 9% before the operation and at 3, 6, and 12 months after
AVR.
Mean and peak gradients for 21-mm and 23-mm valves
at 3-, 6-, and 12-month follow-up are listed in Table 2. For
both 21-mm and 23-mm SBPs, peak gradient reduction
during follow-up was significant (F  17.2, P  .001 and
F  13.4, P  .001, respectively; Figures 1 and 2); the
Bonferroni test showed a significant difference between 3
months and both 6 and 12 months (P  .001). The time
pattern of reduction of peak transprosthetic gradient was not
significantly different between patients with 21-mm and
23-mm SBPs at 2-factor ANOVA (F  0.03, P  .20).
Mean gradient reduction during follow-up was signifi-
cant for both 21-mm and 23-mm SBPs as well (F  11.3,
P .001 and F 7.0, P .001, respectively; Figures 1 and
2); the Bonferroni test showed a significant difference be-
tween 3 and both 6 and 12 months. The time pattern of
reduction of the mean transprosthetic gradient was not sig-
nificantly different between patients with 21-mm and
23-mm SBPs at 2-factor ANOVA (F  1.0, P  .20).
Values of EOA and EOAi at 3-, 6-, and 12-month fol-
low-up are listed in Table 2. For both 21-mm and 23-mm
SBPs, changes in EOAi during follow-up could be due to
chance (F  2.8, P  .06 and F  2.6, P  .07, respec-
tively), and no significant differences between the follow-up
intervals were found at the Bonferroni test. The time pattern
of EOAi change during follow-up was not different between
patients with 21-mm and 23-mm SBPs at 2-factor ANOVA
(F  0.2, P  .20).
Because patient-prosthesis mismatch is more likely in
patients with a large body surface area (BSA) receiving a
21-mm prosthesis, we compared the hemodynamic perfor-
mance of the 21-mm SBP at 1-year follow-up between the
10 patients with BSAs of greater than 1.85 m2 and the 51
patients with BSAs of 1.85 m2 or less. The differences in
peak gradient (23  5 vs 21  8 mm Hg, P  .20), mean
gradient (13  3 vs 11  4 mm Hg, P  .20), and EOAi
(0.93  0.14 cm2/m2 vs 1.01  0.11 cm2/m2, P  .10)
could be due to chance. However, LVMi regression was
TABLE 2. Comparison of echocardiographic data at 3-, 6-, and 12-month follow-up by means of repeated-measures ANOVA
3 mo 6 mo 12 mo P value
21 mm (n  61)
Peak gradient (mm Hg) 25 5 23 5 22 6 .001
Mean gradient (mm Hg) 14 4 12 2 12 3 .001
EOA (cm2) 1.62 0.27 1.65 0.22 1.66 0.24 .08
EOAi (cm2/m2) 0.98 0.12 1.00 0.10 1.00 0.11 .06
LVMi (g/m2) 132 26 126 27 120 27 .001
Left ventricular mass reduction (%) 8 5 13 10 17 11 .001
23 mm (n  121)
Peak gradient (mm Hg) 21 5 20 5 19 6 .001
Mean gradient (mm Hg) 12 3 11 3 11 4 .001
EOA (cm2) 1.93 0.23 1.95 0.23 1.96 0.25 .06
EOAi (cm2/m2) 1.07 0.13 1.08 0.13 1.08 0.14 .07
LVMi (g/m2) 141 33 132 30 123 29 .001
Left ventricular mass reduction (%) 9 6 15 8 21 10 .001
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significantly lower in patients with BSAs of greater than
1.85 m2 (10%  4% vs 17%  11%, P  .03), none of
whom had arterial hypertension.
Trivial aortic regurgitation was observed at transthoracic
echocardiography in 133 (73%) of 182 patients.
Regression of Left Ventricular Hypertrophy
LVMi was evaluated before the operation and at each fol-
low-up interval (Table 2). At preoperative 2-D echocardi-
ography, LVMi was 151  33 g/m2 in the overall popula-
tion, being 145  29 g/m2 in patients receiving a 21-mm
SBP and 154  34 g/m2 in patients receiving a 23-mm SBP
(P  .20). After AVR, LVMi significantly decreased in
patients with both a 21-mm and a 23-mm SBP (F  77.7,
P  .001 and F  156.5, P  .001, respectively; Figures 3
and 4). The Bonferroni test showed a significant difference
between all postoperative values versus preoperative values
(P  .001) and between LVMi values at all follow-up
intervals. Regression of left ventricular hypertrophy during
follow-up was significantly higher in patients with 23-mm
versus 21-mm SBPs at 2-factor ANOVA (F  3.6, P 
.03).
To identify factors that could predict a higher regression
of LV hypertrophy, we looked for correlations between the
percentage change in LVMi at 1 year and BSA, peak
transprosthetic gradient, and EOAi at 1 month. A trend
toward an inverse correlation between BSA and regression
of LV hypertrophy in recipients of the 21-mm SBP (r 
0.17, P  .18) and between peak gradient at 1 month and
regression of LV hypertrophy in the entire population (r 
0.13, P  .08) and in recipients of the 23-mm SBP (r 
0.14, P  .13) were found.
Discussion
All currently available mechanical prostheses are associated
with residual gradients after AVR, particularly in patients
with a small aortic annulus. Considering that small-sized
prostheses (23 mm) represent approximately two thirds of
Figure 1. Transprosthetic pressure gradients in 61 patients with a 21-mm SBP at 3-, 6-, and 12-month follow-up.
Figure 2. Transprosthetic gradients in 121 patients with a 23-mm SBP at 3-, 6-, and 12-month follow-up.
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the mechanical aortic valves implanted annually,9 continu-
ous efforts are made by various manufacturers to improve
prosthesis design, aiming to minimize such gradients and
reduce the risk of patient-prosthesis mismatch.
Clinical Experience With the SBP
Although the SBP has been available for clinical use since
1990 and has been implanted in a massive number of
patients, few reports have been published concerning this
device. The results reported thus far have shown a satisfac-
tory clinical performance with a low incidence of valve-
related complications at short-term2,12,13 and medium-term
follow-up.14-16 Even less data are available on the hemody-
namic performance of the SBP in the aortic position.5-7
Considering that reference values for the EOA of aortic
valve prostheses should be readily available in the operating
room to determine whether a particular prosthesis meets the
requirements to avoid patient-prosthesis mismatch,8 in
1995, we started a study on the SBP by means of serial
echocardiographic examinations during the first year after
AVR. The present echocardiographic study reports a wide
experience including 182 patients who underwent AVR
with a 21-mm or 23-mm SBP.
Hemodynamic Performance
In the present series the SBP has shown a very good
hemodynamic performance, with low gradients in the aver-
age sizes used for AVR, which is in agreement with the 2
reports describing the results with both 21-mm and 23-mm
SBPs. Badano and coworkers5 observed a peak and mean
gradient of 25 mm Hg (range, 15-40 mm Hg) and 13 mm Hg
(range, 15-40 mm Hg) and an EOAi of 0.93 cm2/m2 (range,
Figure 3. Comparison of LVMi before operation and at 3-, 6-, and 12-month follow-up by means of repeated-
measures ANOVA in 61 patients receiving a 21-mm SBP.
Figure 4. Comparison of LVMi before operation and at 3-, 6-, and 12-month follow-up by means of repeated-
measures ANOVA in 121 patients receiving a 23-mm SBP.
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0.69-1.24 cm2/m2) for the 21-mm SBP and peak and a mean
gradient of 18 mm Hg (range, 13-30 mm Hg) and 10 mm Hg
(range, 6-22 mm Hg) and an EOAi of 1.15 cm2/m2 (range,
0.84-1.57 cm2/m2) for the 23-mm SBP. Flameng and co-
workers6 reported peak and mean gradients of 22  7 and
10  3 mm Hg and an EOA of 1.08  0.20 for the 21-mm
SBP and peak and mean gradients of 17  6 and 8  3 mm
Hg and an EOA of 1.55  0.23 for the 23-mm SBP.
Interestingly, hydrodynamic in vitro studies have shown
lower forward-flow pressure decreases and lower total en-
ergy losses for the SBP compared with that seen in other
flat-leaflet models.3,4 In fact, the transprosthetic gradients
observed in the present series compare favorably with those
reported for the same size St Jude Medical standard (St Jude
Medical, Inc, St Paul, Minn),6 CarboMedics (Sulzer Carbo-
medics, Inc, Austin, Tex),17 and ATS Medical (ATS Med-
ical, Inc, Minneapolis, Minn)18 prostheses at a mean fol-
low-up time of 4 months and with those of the Medtronic
Hall19 prosthesis (Medtronic, Inc, Minneapolis, Minn) at a
mean follow-up of 2 years. However, there is not a clear-cut
evidence that design modifications introduced in the SBP
determine a substantial improvement in the hemodynamic
performance of the valve in vivo.
In the present series both 21-mm and 23-mm SBPs
showed a relatively large EOAi (1.00  0.11 and 1.08 
0.14 cm2/m2 at 1 year, respectively), considering that the
EOAi should ideally be no less than 0.85 to 0.90 cm2/m2 to
avoid any significant gradient at rest or during exercise, thus
preventing patient-prosthesis mismatch.8,20 Only 2 (3.5%)
patients with a 21-mm SBP and 1 (0.8%) patient with a
23-mm SBP had an EOAi 0.75 cm2/m2 or less, indicating a
significant degree of patient-prosthesis mismatch.8 How-
ever, these 3 patients were in NYHA class II at the 1-year
follow-up, faring better than some patients with higher
EOAi and no echocardiographic evidence of patient-pros-
thesis mismatch, thus showing that a smaller EOAi is not
the major determinant of the clinical status of patients
receiving a small-sized aortic SBP.
In a study on dobutamine stress echocardiography in 14
patients with a 21-mm SBP, Kadir and coworkers7 reported
an acceptable increase in transprosthetic gradients under
maximum stress (peak gradient, 65  18 mm Hg; mean
gradient, 35  12 mm Hg) without significant changes in
EOAi (0.96  0.43 cm2/m2). In addition, Kadir and co-
workers observed that in patients with a very large BSA
(2 m2), the EOAi was quite small at rest (0.65  0.15
cm2/m2), and the peak transprosthetic gradient under max-
imum stress reached 78 18 mm Hg, showing the presence
of patient-prosthesis mismatch. Nevertheless, Kadir and co-
workers concluded that patient-prosthesis mismatch is not a
clinical problem, even in patients with a large BSA. In the
present series there was no patient with a BSA of 2 m2 or
greater; considering recipients of the 21-mm SBP with
BSAs of greater than 1.85 m2, the EOAi was only slightly
lower than that in patients with smaller BSAs (0.93  0.14
vs 1.01  0.11 cm2/m2, P  .10) and far from indicating
patient-prosthesis mismatch. However, the reduction of LVMi
was significantly lower in patients with BSAs of greater than
1.85 m2 (10% 4% vs 17% 11%, P .03), thus suggesting
that even though a smaller EOAi might not influence the
clinical status of the patient at 1 year, it might reduce or prevent
the regression of left ventricular hypertrophy after AVR.
A further echocardiographic finding was detection of trivial
aortic regurgitation in 73% of our patients, irrespective of
valve size. The presence of trivial regurgitant flow caused by
narrow washing jets on either side of a normally functioning
SBP has been described previously5,6 and might contribute
to reduce the risk of thromboembolic complications.
Regression of Left Ventricular Hypertrophy
In addition to the hemodynamic performance, the present
study also evaluated the regression of left ventricular hy-
pertrophy after AVR with an SBP. Left ventricular mass
decreased throughout the 1 year of follow-up, with the
difference between all postoperative controls being statisti-
cally significant for both the 21-mm and 23-mm SBPs.
Regression of left ventricular hypertrophy was more evident
in patients receiving a 23-mm SBP (P  .03), as could be
anticipated on the basis of the lower pressure gradients and
higher EOAi observed. The latter finding is consistent with
the observations by Gonza´lez-Juanatey and colleagues21
and Sim and associates22 on the influence of prosthesis size
on change in left ventricular mass after AVR. In contrast,
Bech-Hanssen and coworkers23 observed a similar regres-
sion of left ventricular hypertrophy after AVR with a me-
chanical valve, irrespective of prosthesis size. In the present
series, the percentage reduction in left ventricular mass was
slightly lower than that reported by others for different
prostheses.21-23 However, LVMi values at the 1-year fol-
low-up returned within the range of normality in recipients
of both the 21-mm and 23-mm SBPs. In addition, most
reports evaluated left ventricular mass regression at a later
follow-up (average follow-up from 18 months to 8 years
after AVR), and it can be expected that also in our patients
the reduction of left ventricular hypertrophy will extend
beyond the first postoperative year.
A larger prosthesis size appeared to be the only signifi-
cant predictor of a higher regression of left ventricular
hypertrophy. In fact, neither BSA nor peak gradient and
EOAi at 1 month showed a significant correlation with the
percentage reduction in LVMi at 1 year. However, a cutoff
point of BSA of greater than 1.85 m2 could identify a group
of recipients of 21-mm SBPs who showed a significantly
lower regression of left ventricular hypertrophy.
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Study Limitations
The present study describes a large series of serial echocar-
diographic data concerning a single model of aortic me-
chanical valve and represents a useful database on the
hemodynamic performance of the SBP in the aortic posi-
tion. A limitation of our study is represented by the fact that
the echocardiographic studies were performed at rest while
physical or pharmacologic stress transprosthetic gradients
are reported to increase considerably.24,25 However, Kadir
and coworkers7 recently demonstrated with dobutamine
stress echocardiography that the 21-mm SBP has an excel-
lent hemodynamic performance with relatively insignificant
pressure gradient generation under stress conditions. More-
over, at each follow-up interval, we calculated the EOAi,
which remains substantially unchanged in conditions of
increased blood flow,7,26,27 thus representing the single most
useful parameter for the evaluation of the hemodynamic
performance of valve prostheses.
Conclusions
The present study reports serial echocardiographic measure-
ments for 21-mm and 23-mm SBPs and shows low transpros-
thetic pressure gradients with significant reduction of left ven-
tricular hypertrophy during the first year after AVR. The
reported EOA values might be useful for AVR in patients with
a small aortic annulus to avoid patient-prosthesis mismatch.
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